Literature DB >> 24446792

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply.

Hiltrud Brauch1, Matthias Schwab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24446792      PMCID： PMC4137837          DOI： 10.1111/bcp.12330

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  CYP2D6 genotyping and the use of tamoxifen in breast cancer.

Authors:  Donald Berry
Journal:  J Natl Cancer Inst       Date:  2013-08-19       Impact factor: 13.506

2.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

3.  CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer.

Authors:  Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

4.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Authors:  Meredith M Regan; Brian Leyland-Jones; Mark Bouzyk; Olivia Pagani; Weining Tang; Roswitha Kammler; Patrizia Dell'orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Patrick Neven; Marc Debled; Rudolf Maibach; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch; James M Rae; Giuseppe Viale
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

5.  Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  James M Rae; Meredith M Regan; Jacklyn N Thibert; Christina Gersch; Dafydd Thomas; Brian Leyland-Jones; Giuseppe Viale; Lajos Pusztai; Daniel F Hayes; Todd Skaar; Catherine Van Poznak
Journal:  J Natl Cancer Inst       Date:  2013-08-19       Impact factor: 13.506

6.  Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Carol L Rosenberg; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Clin Epidemiol       Date:  2010-10-22       Impact factor: 4.790

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.

Authors:  M J Ratain; Y Nakamura; N J Cox
Journal:  Clin Pharmacol Ther       Date:  2013-08       Impact factor: 6.875

9.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Authors:  Werner Schroth; Matthew P Goetz; Ute Hamann; Peter A Fasching; Marcus Schmidt; Stefan Winter; Peter Fritz; Wolfgang Simon; Vera J Suman; Matthew M Ames; Stephanie L Safgren; Mary J Kuffel; Hans Ulrich Ulmer; Julia Boländer; Reiner Strick; Matthias W Beckmann; Heinz Koelbl; Richard M Weinshilboum; James N Ingle; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch
Journal:  JAMA       Date:  2009-10-07       Impact factor: 56.272

10.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Authors:  James M Rae; Suzy Drury; Daniel F Hayes; Vered Stearns; Jacklyn N Thibert; Ben P Haynes; Janine Salter; Ivana Sestak; Jack Cuzick; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506
View more
  1 in total

Review 1.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.